• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XU Lingya, LIU Xue, CAO Xiaoyang, ZHANG Xinyi, YAO Jing, WANG Chuangong. Effect of ACE2 on the prognosis of breast cancer and its potential mechanism[J]. Journal of China Pharmaceutical University, 2023, 54(5): 586-598. DOI: 10.11665/j.issn.1000-5048.2023033102
Citation: XU Lingya, LIU Xue, CAO Xiaoyang, ZHANG Xinyi, YAO Jing, WANG Chuangong. Effect of ACE2 on the prognosis of breast cancer and its potential mechanism[J]. Journal of China Pharmaceutical University, 2023, 54(5): 586-598. DOI: 10.11665/j.issn.1000-5048.2023033102
shu

Effect of ACE2 on the prognosis of breast cancer and its potential mechanism

  • 1.

    School of Basic Medicine, Weifang Medical University, Weifang 261053

  • 2.

    School of Basic Medical, Jining Medical University, Jining 272067, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81902518)
More Information
  • Received Date: March 30, 2023
  • Revised Date: September 04, 2023
    Graphical Abstract
    • Abstract
  • This study aims to investigate the effect of transmembrane protein angiotensin converting enzyme 2 (ACE2) on the prognosis of breast cancer and its potential mechanism.Public databases were used to analyze ACE2 expression and its relationship with clinicopathological features and prognosis of breast cancer patients, combined with in vitro experiments to analyze the mechanism of action and immune relevance of ACE2 in breast cancer.Results showed that the expression of ACE2 in breast cancer tissues was significantly lower than that in normal breast tissues, and that its expression was negatively correlated with age, M stage and N1mi stage of breast cancer patients (P < 0.05).Patients with Luminal type breast cancer with high ACE2 expression had poor prognosis, while in the triple-negative breast cancer (TNBC) subtype, ACE2 showed different prognostic significance.In addition, ACE2 is closely associated with the metabolic and immune microenvironment of tumor tissue.In vitro experiments have shown that ACE2 is lowly expressed in MDA-MB-231 cells and may inhibit cell progress by downregulating matrix metalloproteinase 2（MMP2）.The results suggest that the low expression of ACE2 in breast cancer is closely associated with patient prognosis as well as metabolic and immune microenvironment, and that ACE2 may inhibit TNBC cell progress through the MMP2 pathway.
    • FullText(HTML)
    • References (23)
  • [1]
    Kocarnik JM, Compton K, Dean FE, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019[J]. JAMA Oncol, 2022, 8(3): 420-444.
    [2]
    Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48.
    [3]
    Liu X, Li YQ, Mu FC, et al. New progress in molecular typing of triple negative breast cancer[J]. Chin J Clin Exp Pathol (临床与实验病理学杂志), 2020, 36(3): 316-319.
    [4]
    Waks AG, Winer EP. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3): 288-300.
    [5]
    Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial[J]. JAMA, 2021, 325(1): 50-58.
    [6]
    Arendse LB, Jan Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure[J]. Pharmacol Rev, 2019, 71(4): 539-570.
    [7]
    Savoia C, Volpe M, Kreutz R. Hypertension, a moving target in COVID-19: current views and perspectives[J]. Circ Res, 2021, 128(7): 1062-1079.
    [8]
    RASSantos, Sampaio WO, Alzamora AC, et al. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)[J]. Physiol Rev, 2018, 98(1): 505-553.
    [9]
    Liu FF, Gong ZK, Liang HL, et al. Progress of the relationship between renin-angiotensin system and tumor[J]. J Mod Oncol (现代肿瘤医学), 2022, 30(8): 1495-1499.
    [10]
    Acconcia F. The network of angiotensin receptors in breast cancer[J]. Cells, 2020, 9(6): 1336.
    [11]
    Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation[J]. Nature, 2012, 487(7408): 477-481.
    [12]
    Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis[J]. Ageing Res Rev, 2020, 62: 101123.
    [13]
    Li ZL, Peng MX, Chen P, et al. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry[J]. Cell Metab, 2022, 34(3): 424-440.
    [14]
    Yu CH, Tang W, Wang YH, et al. Downregulation of ACE2/Ang-(1-7)/Mas axis promotes breast cancer metastasis by enhancing store-operated calcium entry[J]. Cancer Lett, 2016, 376(2): 268-277.
    [15]
    Ye GX, Qin Y, Lu XH, et al. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2015, 459(1): 18-23.
    [16]
    Khanna P, Soh HJ, Chen CH, et al. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma[J]. Sci Transl Med, 2021, 13(577): eabc0170.
    [17]
    Zhang Q, Lu SH, Li TF, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway[J]. J Exp Clin Cancer Res, 2019, 38(1): 173.
    [18]
    Zhang SB, Zhao BB, Gao H, et al. Dexmedetomidine mediated miR-526b-3p/MMP2 pathway affects the invasion and migration of human cervical cancer cell line HeLa[J]. Chin J Birth Heath Hered (中国优生与遗传杂志), 2022, 30(10): 1703-1708.
    [19]
    Jackson CB, Farzan M, Chen B, et al. Mechanisms of SARS-CoV-2 entry into cells[J]. Nat Rev Mol Cell Biol, 2022, 23(1): 3-20.
    [20]
    Brown JM, Wasson MD, Marcato P. Triple-negative breast cancer and the COVID-19 pandemic: clinical management perspectives and potential consequences of infection[J]. Cancers, 2021, 13(2): 296.
    [21]
    Xiao Y, Ma D, Yang YS, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer[J]. Cell Res, 2022, 32(5): 477-490.
    [22]
    Niland S, Riscanevo AX, Eble JA. Matrix metalloproteinases shape the tumor microenvironment in cancer progression[J]. Int J Mol Sci, 2021, 23(1): 146.
    [23]
    Sanyal S, Amin SA, Adhikari N, et al. Ligand-based design of anticancer MMP2 inhibitors: a review[J]. Future Med Chem, 2021, 13(22): 1987-2013.
    • Related Articles

  • Related Articles

    [1]WANG Lixin, JIANG Xiubo, GUO Qiaozhen, WANG Zicheng, WANG Bo, WANG Yuxia, QU Wensheng, DUAN Xiaotao. TM9SF2 promotes proliferation and metastasis of triple negative breast cancer cell line MDA-MB-231[J]. Journal of China Pharmaceutical University, 2021, 52(5): 609-613. DOI: 10.11665/j.issn.1000-5048.20210514
    [2]WANG Kaizhen, YANG Wanwan, XU Shengyao, GUO Qinglong, ZHAO Li. Effects and mechanisms of AKR1C3 inducing doxorubicin resistance in breast cancer[J]. Journal of China Pharmaceutical University, 2021, 52(3): 352-360. DOI: 10.11665/j.issn.1000-5048.20210313
    [3]WU Yubing, YIN Lifang, QIN Chao. Clinical application and detection of matrix metalloproteinases in diagnosis[J]. Journal of China Pharmaceutical University, 2020, 51(5): 614-621. DOI: 10.11665/j.issn.1000-5048.20200514
    [4]ZHENG Binbin, ZHANG Jianan, FAN Yixin, HU Liang, LIU Wentao, WANG Xuerong. Lidocaine attenuates LPS-induced acute lung injury in mice via an inhibition on matrix metalloproteinases[J]. Journal of China Pharmaceutical University, 2020, 51(2): 180-184. DOI: 10.11665/j.issn.1000-5048.20200208
    [5]FAN Yixin, LIU Haijiao, LI Yixuan, ZHANG Yan, LIU Wentao, ZHANG Guangqin. Quercetin ameliorates postoperative pain by suppressing matrix metalloproteinase in microglia[J]. Journal of China Pharmaceutical University, 2017, 48(3): 343-347. DOI: 10.11665/j.issn.1000-5048.20170315
    [6]TU Guogang, WANG Jiaqi, XIONG Shengtao, KUANG Binhai, LI Shaohua. Molecular dynamics simulation of matrix metalloproteinases S′1 binding pocket[J]. Journal of China Pharmaceutical University, 2013, 44(3): 219-222. DOI: 10.11665/j.issn.1000-5048.20130306
    [7]LI Na, CUI Rui-jie, ZHAO Xiao-shun, LIANG Jin-ying. 2-Methyl-3-hydroxy-anthraquinone induces Ca2+-mediated apoptosis in human MCF-7 breast cancer cells[J]. Journal of China Pharmaceutical University, 2011, 42(4): 365-368.
    [8]Effects of astragaloside IV on experimental ventricular remodeling in mice and its mechanism from matrix metalloproteinase aspect[J]. Journal of China Pharmaceutical University, 2010, 41(1): 70-75.
    [10]Matrix Metalloproteinases Changes in Rat Hypertrophic Myocardium Induced by Levothyroxine and the Effect of A New Endothelin Receptor Antagonist CPU-0213[J]. Journal of China Pharmaceutical University, 2004, (2): 53-58.

  • Cited by

    Periodical cited type(1)

    1. 李长青，辛林峰，秦琴，黄慧梅，倪慧，李佳乐，张琳. 剪切DR3第10外显子促进乳腺癌MDA-MB-231细胞株增殖. 华夏医学. 2024(03): 41-47 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (128) PDF downloads (260) Cited by(1)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：275978

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return